{"id":"W4404417044","doi":"10.3390/curroncol31110529","title":"Correction: Alvarado-Miranda et al. Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer. Curr. Oncol. 2023, 30, 6097–6110","year":2024,"lang":"en","type":"erratum","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Capecitabine; Aromatase inhibitor; Aromatase; Human Epidermal Growth Factor Receptor 2; HER2 negative; Internal medicine; Metastatic breast cancer; Hormone receptor; Oncology; Second line; Cancer research; Breast cancer; Cancer; First line","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0006383841,0.001758218,0.003406335,0.0006808011,0.0004251182,0.000122059,0.0005333835,0.0008373698,0.00335697],"category_scores_gemma":[0.0003827699,0.001539332,0.0008990807,0.001116455,0.0007693496,0.0003602285,0.0002554802,0.004183975,0.0005682433],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.005844509,"about_ca_system_score_gemma":0.006208671,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006399066,"about_ca_topic_score_gemma":0.0009113459,"domain_scores_codex":[0.9932672,0.0004432036,0.001627152,0.002219024,0.001034387,0.001409076],"domain_scores_gemma":[0.99445,0.001239904,0.001240184,0.0009563898,0.001377305,0.0007361738],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.01067486,0.001787448,0.000008238251,0.0007782716,0.001806724,0.0001695885,0.001191001,0.00003649901,0.0001724598,0.00003099304,0.7760797,0.2072642],"study_design_scores_gemma":[0.01855762,0.007148055,0.0002612362,0.004577084,0.001344791,0.001033415,0.0006181964,0.001095996,0.0002103601,0.000328301,0.9635051,0.001319781],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"editorial","genre_gemma":"review","genre_scores_codex":[0.001387562,0.3646345,0.002966194,0.1456098,0.414045,0.01695604,0.04772904,0.001173948,0.005497975],"genre_scores_gemma":[0.004297513,0.4568835,0.004954153,0.03542647,0.08289926,0.03856032,0.07567264,0.003094162,0.298212],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.3311458,"threshold_uncertainty_score":0.9995164,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04541429623633902,"score_gpt":0.3958328626615461,"score_spread":0.3504185664252071,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}